Are antimicrobials still the future of respiratory infection therapy? Source: Virtual Congress 2021 – Emerging data for the management of respiratory tract infections Year: 2021
Antibiotic resistance in pulmonary infections: mechanisms and epidemiology Source: Eur Respir Monogr 2017; 75: 21-43 Year: 2017
Antibiotic resistance and clinical outcomes: the CAPNETZ experience Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections Year: 2006
Antibiotic prescribing for adults with acute cough/lower respiratory tract infection: congruence with guidelines Source: Eur Respir J 2011; 37: 112-118 Year: 2011
Epidemiological impact of antibiotic use/misuse in the community Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=165 Year: 2004
From the bedside: upcoming new clinical strategies: novel strategies to combat respiratory viral infections Source: International Congress 2017 – Scientific year in review Year: 2017
Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones}, Source: Eur Respir J 2012; 40: 814-822 Year: 2012
Antibiotic prescribing in acute respiratory infections – are we following guidelines? Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006
Antibiotic stewardship in respiratory infections Source: International Congress 2016 – Respiratory infections in high-income countries: old challenges and new threats Year: 2016
Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis? Source: Eur Respir J 2010; 35: 606-613 Year: 2010
International guidelines for nosocomial pneumonia: do they cover multidrug resistance management? Source: International Congress 2019 – Multidrug resistance in nosocomial pneumonia: burden, magnitude and solution Year: 2019
Future antibiotics and current practices for treating respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=255 Year: 2004
Advances in the diagnosis of mycobacteria infections and challenges of drug susceptibility testing Source: International Congress 2019 – New guidelines for treatment of nontuberculous mycobacterial pulmonary disease Year: 2019
Empiric antibiotic treatment and pathogens resistance in respiratory tract infections; a prospective epidemiological survey Source: Eur Respir J 2003; 22: Suppl. 45, 335s Year: 2003
Non-pharmacological factors for the emergence of drug resistance in patients of pulmonary tuberculosis: An Indian overview Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012
Improved diagnostics and diagnostic approaches: The role in the fight to emerging infectious diseases (EID) and antimicrobial resistance (AMR) Source: Postgraduate course 2021: PG7 - Postgraduate course : Emerging infectious diseases and antimicrobial resistance: diagnostics, treatments, vaccines and other preventive and/or therapeutic interventions Year: 2021
Potential impact and relevance of diagnostics in the management of respiratory tract infections: from COVID to hospital-acquired pneumonia Source: Virtual Congress 2021 – Emerging data for the management of respiratory tract infections Year: 2021
The challenges of severe pneumonia: new pathogens, new drugs and new formulations Source: Virtual Congress 2021 – Respiratory infections Year: 2021
Could the initial use of antipseudomonal agents improve the prognosis for non-hospital acquired pneumonia? Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013